Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study

doi:10.12998/wjcc.v6.i5.74

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 6, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9873)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-6) series.

Item

Count

PDF

633

WORD

352

HTML

3635

Figures (1-1)

279

Tables (1-6)

291

Sum=5190

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

753

Download

1093

Sum=1846

Publishing Process of This Article

Item

Count

Browse

1077

Download

1760

Sum=2837

May 16, 2018 (publication date) through Jan 11, 2025

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Cases. May 16, 2018; 6(5): 74-83
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74

Table 4 Comparison of overall survival in patients with hepatocellular carcinoma treated with sorafenib and those treated with sorafenib plus transarterial chemoembolization

	Annual survival rate (%)			mOS (mo)	P value
	1 yr	2 yr	3 yr	mOS (mo)	P value
Sorafenib + TACE	94.7	63.2	34.6	35.2	< 0.001
TACE	96.6	42	NA	22	< 0.001

None of the patients collected in the TACE treatment group achieved a 3-year survival time. mOS: Median overall survival; TACE: Transarterial chemoembolization.

Citation: Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83
URL: https://www.wjgnet.com/2307-8960/full/v6/i5/74.htm
DOI: https://dx.doi.org/10.12998/wjcc.v6.i5.74